Agency: Cordis | Branch: H2020 | Program: RIA | Phase: WATER-2b-2015 | Award Amount: 7.90M | Year: 2016
Land, food, energy, water and climate are interconnected, comprising a coherent system (the Nexus), dominated by complexity and feedback. The integrated management of the Nexus is critical to secure the efficient and sustainable use of resources. Barriers to a resource efficient Europe are policy inconsistencies and incoherence, knowledge gaps, especially regarding integration methodologies and tools for the Nexus, and knowledge and technology lock-ins. SIM4NEXUS will develop innovative methodologies to address these barriers, by building on well-known and scientifically established existing thematic models, simulating different components/themes of the Nexus and by developing: (a) novel complexity science methodologies and approaches for integrating the outputs of the thematic models; (b) a Geoplatform for seamless integration of public domain data and metadata for decision and policy making; (c) a Knowledge Elicitation Engine for integrating strategies at different spatial and temporal scales with top down and bottom up learning process, discovering new and emergent knowledge, in the form of unknown relations between the Nexus components and policies/strategies; (d) a web-based Serious Game for multiple users, as an enhanced interactive visualisation tool, providing an immersive experience to decision- and policy-makers. The Serious Game will assist the users (as players) in better understanding and visualising policies at various geo-/spatial scales and from a holistic point of view, towards a better scientific understanding of the Nexus. The Serious Game will be validated (applied, tested, verified and used) via ten Case Studies ranging from regional to national level. Two further Strategic Serious Games at European and Global levels will also be developed for demonstration, education and further exploitation purposes, accompanied by a robust business plan and IPR framework, for taking advantage of the post-project situation and business potential.
Agency: Cordis | Branch: H2020 | Program: RIA | Phase: INFRAIA-1-2014-2015 | Award Amount: 9.98M | Year: 2015
HYDRALAB is an advanced network of environmental hydraulic institutes in Europe, which has been effective in providing access to a suite of major and unique environmental hydraulic facilities from across the whole European scientific community. A continuation project will prepare environmental hydraulic modelling for the upcoming urgent technical challenges associated with adaptations for climate change. A multi-disciplinary approach is essential to meet these challenges. We denote the project HYDRALAB\, in recognition of the added value that will follow from our network changing to enhance the collaboration between specialists and engaging with a new range of stakeholders. The issues associated with climate change impacts on rivers and coasts are significant enough to ask the scientific community to which we open up our facilities to focus their research efforts on adaptations for climate change. We plan to issue themed calls for proposals for access to the facilities, with scientific merit as the main selection criterion, but with preference to the proposals that also address issues of adaptation to climate change impact. In HYDRALAB\, with the prospect of climate change, we will build networking activities that will also involve the wider hydraulic community in the process of generating the deliverables of the project. The first Workshop in the project will be devoted to working together with the larger European hydraulics community not directly involved in HYDRALAB. Increased emphasis will be placed by HYDRALAB\ on engagement with industry a theme that will be delivered initially through the vehicle of a focussed Workshop between HYDRALAB researchers and industry. We will work together with industry to have HYDRALAB\ become part of the innovation cycle by bringing development to market this is particularly relevant for the instruments we develop - to involve industry in our range of project deliverables.
Agency: Cordis | Branch: H2020 | Program: RIA | Phase: SFS-11b-2015 | Award Amount: 6.92M | Year: 2016
Aquaculture is one of five sectors in the EUs Blue Growth Strategy, aimed at harnessing untapped potential for food production and jobs whilst focusing on environmental sustainability. TAPAS addresses this challenge by supporting member states to establish a coherent and efficient regulatory framework aimed at sustainable growth. TAPAS will use a requirements analysis to evaluate existing regulatory and licensing frameworks across the EU, taking account of the range of production environments and specificities and emerging approaches such as offshore technologies, integrated multi-trophic aquaculture, and integration with other sectors. We will propose new, flexible approaches to open methods of coordination, working to unified, common standards. TAPAS will also evaluate existing tools for economic assessment of aquaculture sustainability affecting sectoral growth. TAPAS will critically evaluate the capabilities and verification level of existing ecosystem planning tools and will develop new approaches for evaluation of carrying capacities, environmental impact and future risk. TAPAS will improve existing and develop new models for far- and near-field environmental assessment providing better monitoring, observation, forecasting and early warning technologies. The innovative methodologies and components emerging from TAPAS will be integrated in an Aquaculture Sustainability Toolbox complemented by a decision support system to support the development and implementation of coastal and marine spatial planning enabling less costly, more transparent and more efficient licensing. TAPAS partners will collaborate with key industry regulators and certifiers through case studies to ensure the acceptability and utility of project approach and outcomes. Training, dissemination and outreach activities will specifically target improvement of the image of European aquaculture and uptake of outputs by regulators, while promoting an integrated sustainable strategy for development.
Agency: Cordis | Branch: H2020 | Program: IA | Phase: PILOTS-02-2016 | Award Amount: 8.80M | Year: 2017
NanoPack will demonstrate a solution for extending food shelf life by using novel smart antimicrobial surfaces, applied in active food packaging products. It will run pilot lines in operational industrial environments to manufacture commercially feasible antimicrobial polymer films, accepted by consumers. It will minimize the amount of preservatives required to maintain freshness, add value and assure safety to the entire supply chain. The project will employ natural Halloysite Nanotubes (HNTs) as reliable and safe carriers of bio-active compounds which are unable to migrate from the food packaging into food. Maximising safety, they slowly release minute amounts of potent, volatile and broad-spectrum natural agents into the packaging headspace. Using nanotechnology enables 1) introducing sensitive molecules into polymer films; 2) anti-microbial functionality without impaired film properties; 3) manufacturing potent antimicrobial surfaces with tunable properties, while creating a pH-triggered gate keeper effect to slow down release of the payload encapsulated. The resulting film will exhibit antimicrobial properties unmet by the current state-of-the-art. The processes across the supply chain will be validated through 5 pilot runs on existing production lines: 1) loading antimicrobials, 2) anti-microbial HNT polymer production, 3) anti-microbial packaging film production and 4-5) using the novel packaging on food products. Commercial feasibility will be assessed, including consumer acceptance and legal, regulatory, safety and environmental aspects. The success of NanoPack will result in validated consumer-accepted nanotechnology-based antimicrobial food packaging that will enhance food safety, prevent foodborne illness outbreaks and reduce food waste caused by early spoilage. Better performing, safer and smarter products will position Europe as the leader in food nanotechnology & smart antimicrobial packaging while increasing competitiveness and industry growth.
News Article | February 15, 2017
SAN DIEGO, CA --(Marketwired - February 08, 2017) - Quidel Corporation ( : QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the fourth quarter and year ended December 31, 2016. Total revenue for the fourth quarter of 2016 was $52.8 million, versus $52.4 million in the fourth quarter of 2015. The 1% increase in revenue was primarily due to higher sales of Immunoassay, Molecular and Specialty products, partially offset by a decrease in Virology and Grant revenue in the fourth quarter of 2016. Immunoassay product revenue increased 5% in the fourth quarter, led by a 17% rise in Sofia revenue, partially offset by a 4% decline in total QuickVue sales. During the fourth quarter of 2016, the Virology category declined 12%, while the Molecular category grew 72% to $2.7 million. Specialty Products grew 23%, and the Other revenue category decrease was affected by $1.9 million in grant revenue recognized in the fourth quarter of 2015 that was not repeated in 2016. "Our fourth quarter results were softened by two factors. First, although states like Florida, North Carolina and some others saw earlier starts to the influenza season than last year, many did not. And second, while data in our Virena cloud indicated increasing Sofia influenza test usage and positivity rates in many states in December, distributors consumed their inventories to levels that were roughly two-thirds of what they were at the end of 2015," said Douglas Bryant, president and CEO of Quidel Corporation."On the positive side, Sofia placements were significant, as anticipated, and our molecular franchise grew nicely, driven by the launch of multiple Solana assays earlier in the year." Cost of Sales in the fourth quarter of 2016 increased $1.0 million to $19.1 million, the result of unfavorable product mix and increased depreciation from Sofia instruments. Gross margin for the quarter was 64% as compared to 65% for the same period last year, due to lower grant revenue and product mix. R&D expense decreased by $2.4 million in the fourth quarter as compared to the same period last year, primarily due to reduced spend on Savanna and Sofia. Sales and Marketing expense decreased by $0.6 million in the fourth quarter of 2016, as compared to the fourth quarter of 2015 largely due to reduced commercial personnel costs. G&A expense decreased by $0.9 million in the quarter, primarily due to the elimination of the Medical Device Excise Tax and lower stock compensation expense. Net loss for the fourth quarter of 2016 was $2.0 million, or $(0.06) per share, as compared to net loss of $0.4 million, or $(0.01) per share, for the fourth quarter of 2015. On a non-GAAP basis, excluding amortization of intangibles, stock compensation expense and certain non-recurring items, net income for the fourth quarter of 2016 was $5.8 million, or $0.17 per diluted share, as compared to net income of $3.5 million, or $0.10 per diluted share, for the same period in 2015. Full Year 2016 Results Total revenues for the twelve-month period ended December 31, 2016 were $191.6 million, as compared to $196.1 million for 2015. The 2% decrease in revenue was primarily driven by weaker Immunoassay and Virology that offset increased Molecular and Specialty Products sales in the fourth quarter of 2015. Immunoassay revenue in 2016 declined 7% over 2015 to $121.4 million. Sofia revenue accounted for 42% of the total Immunoassay revenue, and QuickVue revenue accounted for 58%. Virology revenue sales decreased 8% over the same period to $40.1 million. Molecular revenue for the year grew 75% from the prior year to $9.5 million. Specialty Product revenue grew 25% to $11.2 million due to the Immutopics acquisition in the first quarter of 2016, and Other category revenue grew 23% to $9.4 million. Cost of Sales for the full year 2016 increased by $1.7 million over 2015 to $73.4 million due to unfavorable product mix, with lower Influenza product sales in the same period as compared to the prior year. R&D expense for 2016 increased by $3.2 million over last year primarily due to an increase in development spending for the Savanna MDx platform and our next generation Sofia instrument, and an increase in clinical trials spending for our Solana and Sofia products. Sales and Marketing expense remained relatively flat over prior year. G&A decreased by $2.4 million in 2016, primarily due to reduced business development expenditures, as well as the suspension of the Medical Device Excise Tax. These decreases were partially offset by increased integration costs associated with the acquisition of Immutopics. For the year ended 2016, net loss was $13.8 million, or $(0.42) per share, as compared to a net loss of $6.1 million, or $(0.18) per share, for the year ended 2015. On a non-GAAP basis, net income for the year ended 2016 was $6.2 million, or $0.19 per diluted share, as compared to net income of $11.2 million, or $0.32 per diluted share, for the year ended 2015. Modification of Revenue Reporting Categories During the fourth quarter of 2016, Quidel (the "company") modified its presentation of revenue to reflect how management strategically thinks about the business categories. In association with the change, the revenues of QuickVue® and Sofia® businesses will be reported within the company's Immunoassay category, and the revenues of Solana®, AmpliVue® and Lyra® products will be reported in the company's Molecular category. Quidel's Thyretain® and Diagnostic Hybrids, or DHI, revenues will be reported in the company's Virology category, and the Specialty Products Group, or SPG, revenues will be reported in the company's Specialty Products category. To view the original press release document describing this change, please visit Quidel's Investor Relations website at http://ir.quidel.com. Non-GAAP Financial Information The Company is providing non-GAAP financial information to exclude the effect of stock-based compensation, amortization of intangibles and certain non-recurring items on earnings (loss) and net earnings (loss) per share as a supplement to its consolidated financial statements, which are presented in accordance with generally accepted accounting principles in the U.S., or GAAP. Management is providing the adjusted net earnings (loss) and adjusted net earnings (loss) per share information for the periods presented because it believes this enhances the comparison of the Company's financial performance from period-to-period, and to that of its competitors. This press release is not meant to be considered in isolation, or as a substitute for results prepared in accordance with GAAP. A reconciliation of the non-GAAP financial measures to the comparable GAAP measures is included in this press release as part of the attached financial tables. Conference Call Information Quidel management will host a conference call to discuss the fourth quarter and full year 2016 results as well as other business matters today beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). During the conference call, management may answer questions concerning business and financial developments and trends. Quidel's responses to these questions, as well as other matters discussed during the conference call, may contain or constitute material information that has not been previously disclosed. To participate in the live call by telephone from the U.S., dial 877-930-5791, or from outside the U.S. dial 253-336-7286, and enter the pass code 5792-7056. A live webcast of the call can be accessed at http://www.quidel.com, and the Web site replay will be available for 14 days. The telephone replay will be available for 48 hours beginning at 8:00 p.m. Eastern Time (5:00 p.m. Pacific Time) today by dialing 855-859-2056 from the U.S., or 404-537-3406 for international callers, and entering pass code 5792-7056. Quidel Corporation serves to enhance the health and well-being of people around the globe through the development of diagnostic solutions that can lead to improved patient outcomes and provide economic benefits to the healthcare system. Marketed under the Sofia ®, QuickVue ® , D3 ® Direct Detection and Thyretain ® leading brand names, as well as under the new Solana ® , AmpliVue ® and Lyra™ molecular brands, Quidel's products aid in the detection and diagnosis of many critical diseases and conditions, including, among others, influenza, respiratory syncytial virus, Strep A, herpes, pregnancy, thyroid disease and fecal occult blood. Quidel's research and development engine is also developing a continuum of diagnostic solutions from advanced lateral-flow and direct fluorescent antibody to molecular diagnostic tests to further improve the quality of healthcare in physicians' offices and hospital and reference laboratories. For more information about Quidel's comprehensive product portfolio, visit quidel.com. This press release contains forward-looking statements within the meaning of the federal securities laws that involve material risks, assumptions and uncertainties. Many possible events or factors could affect our future financial results and performance, such that our actual results and performance may differ materially from those that may be described or implied in the forward-looking statements. As such, no forward-looking statement can be guaranteed. Differences in actual results and performance may arise as a result of a number of factors including, without limitation, fluctuations in our operating results resulting from seasonality, the timing of the onset, length and severity of cold and flu seasons, government and media attention focused on influenza and the related potential impact on humans from novel influenza viruses, adverse changes in competitive conditions in domestic and international markets, changes in sales levels as it relates to the absorption of our fixed costs, lower than anticipated market penetration of our products, the reimbursement system currently in place and future changes to that system, changes in economic conditions in our domestic and international markets, the quantity of our product in our distributors' inventory or distribution channels, changes in the buying patterns of our distributors, and changes in the healthcare market and consolidation of our customer base; our development and protection of intellectual property; our development of new technologies, products and markets; our reliance on a limited number of key distributors; our reliance on sales of our influenza diagnostics tests; our ability to manage our growth strategy, including our ability to integrate companies or technologies we have acquired or may acquire; intellectual property risks, including but not limited to, infringement litigation; our debt service requirements; our inability to settle conversions of our Convertible Senior Notes in cash; the effect on our operating results from the trigger of the conditional conversion feature of our Convertible Senior Notes; the possibility that we may incur additional indebtedness; our need for additional funds to finance our operating needs; volatility and disruption in the global capital and credit markets; acceptance of our products among physicians and other healthcare providers; competition with other providers of diagnostic products; adverse actions or delays in new product reviews or related to currently-marketed products by the U.S. Food and Drug Administration (the "FDA"); changes in government policies; compliance with other government regulations, such as safe working conditions, manufacturing practices, environmental protection, fire hazard and disposal of hazardous substances; third-party reimbursement policies; our ability to meet demand for our products; interruptions in our supply of raw materials; product defects; business risks not covered by insurance and exposure to other litigation claims; interruption to our computer systems; competition for and loss of management and key personnel; international risks, including but not limited to, compliance with product registration requirements, exposure to currency exchange fluctuations and foreign currency exchange risk sharing arrangements, longer payment cycles, lower selling prices and greater difficulty in collecting accounts receivable, reduced protection of intellectual property rights, political and economic instability, taxes, and diversion of lower priced international products into U.S. markets; dilution resulting from future sales of our equity; volatility in our stock price; provisions in our charter documents, Delaware law and our Convertible Senior Notes that might delay or impede stockholder actions with respect to business combinations or similar transactions; and our intention of not paying dividends. Forward-looking statements typically are identified by the use of terms such as "may," "will," "should," "might," "expect," "anticipate," "estimate," "plan," "intend," "goal," "project," "strategy," "future," and similar words, although some forward-looking statements are expressed differently. The risks described in reports and registration statements that we file with the Securities and Exchange Commission (the "SEC") from time to time, should be carefully considered. You are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date of this press release. Except as required by law, we undertake no obligation to publicly release the results of any revision or update of these forward-looking statements, whether as a result of new information, future events or otherwise.
Agency: Cordis | Branch: H2020 | Program: RIA | Phase: EO-3-2016 | Award Amount: 2.00M | Year: 2016
The CEASELESS project will demonstrate how the new Sentinel measurements can support the development of a coastal dimension in Copernicus by providing an unprecedented level of resolution/ accuracy/continuity with respect to present products. The retrieval and validation for restricted domains and for an enlarged set of combined variables (user oriented) will be the basis to advance the state of the art in assimilation, modelling and applications, at a level commensurate with the new Sentinel capabilities. The project will address the multiple scales coexisting in littoral areas by developing new shallow water parameterizations, introducing them into coupled model suites (wind-wave-surge-current-land discharge) and producing new standards for coastal simulations and analyses. The permanent data base, with dynamic repositories, plus the modular structure of the developed models will demonstrate the technical feasibility of a future operational Copernicus coastal service. The set of derived products will be ingested into the users work routines, proving the economic feasibility of the Copernicus coastal extension. The level of conflicts in squeezed coastal zones, expected to grow in the face of climate change, will, thus, benefit directly from CEASELESS, establishing tangible contributions for a wide range of economic sectors. The data repositories (accessible via a dedicated portal), regularly updated with the evolving (satellite-derived) bathymetry will facilitate the use/re-use of our high resolution results, supporting a new set of Copernicus coastal applications such as renewable energy, coastal erosion or harbour exploitation. The mutual validation of satellite data, numerical results and in-situ observations will generate reciprocal profit for enhanced competiveness of EU coastal industries where we shall also explore the suitability for cases in 3rd countries, opening new business opportunities for a coastal Copernicus.
News Article | December 1, 2016
This report studies sales (consumption) of Wind Gear Box in Global market, especially in United States, China, Europe, Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering Winergy Bosch Rexroth Broadwind Energy Moventas Zollern Ishibashi NGC Gears GE Flender Gamesa China Transmission Chongqing Gearbox DHI DCW Group China National Erzhong Group Hangzhou Advance Gearbox Group Ningbo Donly transmission equipment Guo Dian United Power Hansen transmissions company TaiYuan Heavy Industry Shenyang Blower Works Group View Full Report With Complete TOC, List Of Figure and Table: http://globalqyresearch.com/global-wind-gear-box-sales-market-report-2016 Market Segment by Regions, this report splits Global into several key Regions, with sales (consumption), revenue, market share and growth rate of Wind Gear Box in these regions, from 2011 to 2021 (forecast), like United States China Europe Japan Split by product Types, with sales, revenue, price and gross margin, market share and growth rate of each type, can be divided into Type I Type II Type III Split by applications, this report focuses on sales, market share and growth rate of Wind Gear Box in each application, can be divided into Application 1 Application 2 Application 3 Global Wind Gear Box Sales Market Report 2016 1 Wind Gear Box Overview 1.1 Product Overview and Scope of Wind Gear Box 1.2 Classification of Wind Gear Box 1.2.1 Type I 1.2.2 Type II 1.2.3 Type III 1.3 Application of Wind Gear Box 1.3.1 Application 1 1.3.2 Application 2 1.3.3 Application 3 1.4 Wind Gear Box Market by Regions 1.4.1 United States Status and Prospect (2011-2021) 1.4.2 China Status and Prospect (2011-2021) 1.4.3 Europe Status and Prospect (2011-2021) 1.4.4 Japan Status and Prospect (2011-2021) 1.5 Global Market Size (Value and Volume) of Wind Gear Box (2011-2021) 1.5.1 Global Wind Gear Box Sales and Growth Rate (2011-2021) 1.5.2 Global Wind Gear Box Revenue and Growth Rate (2011-2021) 7 Global Wind Gear Box Manufacturers Analysis 7.1 Winergy 7.1.1 Company Basic Information, Manufacturing Base and Competitors 7.1.2 Wind Gear Box Product Type, Application and Specification 22.214.171.124 Type I 126.96.36.199 Type II 7.1.3 Winergy Wind Gear Box Sales, Revenue, Price and Gross Margin (2011-2016) 7.1.4 Main Business/Business Overview 7.2 Bosch Rexroth 7.2.1 Company Basic Information, Manufacturing Base and Competitors 7.2.2 112 Product Type, Application and Specification 188.8.131.52 Type I 184.108.40.206 Type II 7.2.3 Bosch Rexroth Wind Gear Box Sales, Revenue, Price and Gross Margin (2011-2016) 7.2.4 Main Business/Business Overview 7.3 Broadwind Energy 7.3.1 Company Basic Information, Manufacturing Base and Competitors 7.3.2 132 Product Type, Application and Specification 220.127.116.11 Type I 18.104.22.168 Type II 7.3.3 Broadwind Energy Wind Gear Box Sales, Revenue, Price and Gross Margin (2011-2016) 7.3.4 Main Business/Business Overview 7.4 Moventas 7.4.1 Company Basic Information, Manufacturing Base and Competitors 7.4.2 Nov Product Type, Application and Specification 22.214.171.124 Type I 126.96.36.199 Type II 7.4.3 Moventas Wind Gear Box Sales, Revenue, Price and Gross Margin (2011-2016) 7.4.4 Main Business/Business Overview 7.5 Zollern 7.5.1 Company Basic Information, Manufacturing Base and Competitors 7.5.2 Product Type, Application and Specification 188.8.131.52 Type I 184.108.40.206 Type II 7.5.3 Zollern Wind Gear Box Sales, Revenue, Price and Gross Margin (2011-2016) 7.5.4 Main Business/Business Overview 7.6 Ishibashi 7.6.1 Company Basic Information, Manufacturing Base and Competitors 7.6.2 Million USD Product Type, Application and Specification 220.127.116.11 Type I 18.104.22.168 Type II 7.6.3 Ishibashi Wind Gear Box Sales, Revenue, Price and Gross Margin (2011-2016) 7.6.4 Main Business/Business Overview 7.7 NGC Gears 7.7.1 Company Basic Information, Manufacturing Base and Competitors 7.7.2 Machinery & Equipment Product Type, Application and Specification 22.214.171.124 Type I 126.96.36.199 Type II 7.7.3 NGC Gears Wind Gear Box Sales, Revenue, Price and Gross Margin (2011-2016) 7.7.4 Main Business/Business Overview 7.8 GE 7.8.1 Company Basic Information, Manufacturing Base and Competitors 7.8.2 Product Type, Application and Specification 188.8.131.52 Type I 184.108.40.206 Type II 7.8.3 GE Wind Gear Box Sales, Revenue, Price and Gross Margin (2011-2016) 7.8.4 Main Business/Business Overview 7.9 Flender 7.9.1 Company Basic Information, Manufacturing Base and Competitors 7.9.2 Product Type, Application and Specification 220.127.116.11 Type I 18.104.22.168 Type II 7.9.3 Flender Wind Gear Box Sales, Revenue, Price and Gross Margin (2011-2016) 7.9.4 Main Business/Business Overview 7.10 Gamesa 7.10.1 Company Basic Information, Manufacturing Base and Competitors 7.10.2 Product Type, Application and Specification 22.214.171.124 Type I 126.96.36.199 Type II 7.10.3 Gamesa Wind Gear Box Sales, Revenue, Price and Gross Margin (2011-2016) 7.10.4 Main Business/Business Overview 7.11 China Transmission 7.12 Chongqing Gearbox 7.13 DHI DCW Group 7.14 China National Erzhong Group 7.15 Hangzhou Advance Gearbox Group 7.16 Ningbo Donly transmission equipment 7.17 Guo Dian United Power 7.18 Hansen transmissions company 7.19 TaiYuan Heavy Industry 7.20 Shenyang Blower Works Group Global QYResearch ( http://globalqyresearch.com/ ) is the one spot destination for all your research needs. Global QYResearch holds the repository of quality research reports from numerous publishers across the globe. Our inventory of research reports caters to various industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. With the complete information about the publishers and the industries they cater to for developing market research reports, we help our clients in making purchase decision by understanding their requirements and suggesting best possible collection matching their needs.
News Article | February 21, 2017
TORONTO, ONTARIO--(Marketwired - Feb. 21, 2017) - Claren Energy Corp. ("Claren" or the "Company") (TSX VENTURE:CEN) is pleased to provide a corporate update to shareholders. Claren has completed its wellsite operations on the Bobocu 310 side-track well, onshore Romania. The Company completed cased-hole well tests on the Lobe G and Corcova sandstone reservoirs and also tested Lobe H above Lobe G. The cased-hole wireline logging program provided further insight into selecting prospective reservoir units to be tested, and showed gas saturations between 30% to 40%. Unfortunately, upon testing, none of the perforated zones flowed commercial quantities of gas, instead producing gas saturated water and sand. The tests did however confirm the validity of the exploration model which is primarily based on the detection of gas on seismic data as a DHI ("Direct Hydrocarbon Indicator"). As predicted by the seismic data, gas sands were found at the anticipated depth, but gas saturations were below the Company's expectations. This is the completion of Phase I of the proposed work program, in which Phase II includes the drilling of a second well, the Blueray prospect. Although the well tests did not indicate commercial gas quantities at the drilled location this will not change our positive assessment of the Bobocu gas field. Within the Bobocu gas field, "Well 70" historically produced 2 Bcf of gas, and "Well 73" tested 2.5 MMcf per day of gas from the Blueray prospect. "We will study the results of this well and update our reservoir model with respect to the sand and water mobility characteristics specific to this field. Our seismic data will be re-calibrated for reservoirs with variable gas saturation. In addition, Claren plans to re-enter 2 existing wells that produced from the Blueray prospect and run cased-hole logs to confirm the presence of gas "behind-pipe". This will largely de-risk the drilling of the much larger Blueray prospect which will allow us to earn an additional 40% of the concession," stated Henry Aldorf, Claren's Chairman and CEO. Claren is continuing to build a diverse portfolio of low-cost, high-margin international oil and gas assets, and is aggressively pursuing the acquisition of near-term producing assets. The Company is also engaging potential partners to share the financial and technical risk on PEL 112 and PEL 444 in the Cooper Eromanga Basin, in South Australia. Claren Energy Corp. is an oil and gas company that has the right to acquire up to an eighty percent (80%) participating interest in the Bobocu License, onshore Romania. Claren also has a 51.49% working interest in two onshore petroleum exploration licenses ("PELs"), being PEL 112 and PEL 444, including a 1.47% gross overriding royalty interest on the PELs, located on the western flank of the Cooper Eromanga Basin in the State of South Australia, Australia. Its common shares trade on the TSX Venture Exchange under the symbol "CEN". This news release contains forward-looking information relating to Claren's intentions to conduct the drilling programs and other statements that are not historical facts. Such forward-looking information is subject to important risks and uncertainties that could cause actual results to differ materially from what is currently expected, for example: risks related to oil and gas exploration, development, exploitation, production, marketing and transportation, loss of markets, volatility of commodity prices, currency fluctuations, competition from other producers, inability to retain drilling rigs and other services, reliance on key personnel, and insurance risks. Although the present drill program has encountered the presence of gas, it does not necessary indicate that Claren will be successful in its drilling programs. Findings by other oil and gas issuers does not necessarily indicate that Claren will be successful in making such findings in Australia and Romania. In making such forward- looking statements, Claren has relied upon certain assumptions relating to geological settings, commodity prices, the stability of markets and currencies and the availability of capital to Claren in order to continue with the seismic and drilling programs. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While Claren may elect to, Claren is under no obligation and does not undertake to update this information at any particular time, except as required by applicable securities law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
News Article | February 28, 2017
FORT WORTH, Texas--(BUSINESS WIRE)--D.R. Horton, Inc. (NYSE:DHI), America’s Builder, announced that the Company will make a presentation to the investment community via webcast at the Raymond James 38th Annual Institutional Investors Conference on Tuesday, March 7, 2017 at 9:15 a.m. Eastern Time. The presentation may be accessed through the Investor Relations page of the D.R. Horton website at investor.drhorton.com. Listeners are encouraged to go to the site at least five minutes before the scheduled presentation time. A replay of the presentation will be available within 24 hours of the presentation and may be accessed until March 14, 2017. D.R. Horton, Inc., America’s Builder, has been the largest homebuilder by volume in the United States for fifteen consecutive years. Founded in 1978 in Fort Worth, Texas, D.R. Horton has operations in 78 markets in 26 states across the United States and closed 41,652 homes in the twelve-month period ended December 31, 2016. The Company is engaged in the construction and sale of high-quality homes through its diverse brand portfolio that includes D.R. Horton, Emerald Homes, Express Homes and Freedom Homes ranging from $100,000 to over $1,000,000. D.R. Horton also provides mortgage financing and title services for homebuyers through its mortgage and title subsidiaries.
News Article | November 10, 2016
DALLAS, Nov. 10, 2016 (GLOBE NEWSWIRE) -- Ascendant Solutions, Inc. (Pink Sheets:ASDS) (“Ascendant” or the “Company”) today announced its results for the third quarter of fiscal 2016. The Company reported third quarter Consolidated Earnings before Interest, Taxes, Depreciation and Amortization (“EBITDA”) of $162,000 compared to consolidated EBITDA of $326,000 in 2015. For the nine months ended September 30, 2016, the Company reported Consolidated Earnings before Interest, Taxes, Depreciation and Amortization (“EBITDA”) of $503,000 compared to consolidated EBITDA of $464,000 in 2015. For the third quarter ended September 30, 2016, the Company reported a consolidated net loss of $221,000, or $0.01 per share, compared to a net loss of $27,000, or less than $0.01 per share, for the same period of 2015. Consolidated net loss for the nine months ended September 30, 2016 was $760,000 compared to net loss of $306,000 for the nine months ended 2015. “Revenues and gross margins for the third quarter have declined in 2016 due to the impact of lower reimbursements from Medicare and insurers, which is also affecting the broader pharmaceutical industry,” said Mark Heil, President and CFO. “In addition, unexpected direct and indirect remuneration fees (DIR) associated with Medicare Part D also impacted our gross margins for the quarter. We have been working diligently to address this situation and believe we will see positive impact from these initiatives and improved margins for our fourth quarter.” The Company’s subsidiary, Dougherty’s Holding, Inc. (“DHI”), which owns and operates multiple Dougherty’s Pharmacies, reported EBITDA of $280,000 for the third quarter ended September 30, 2016, compared to $464,000 in 2015, a decrease of 39.7%. EBITDA for the nine months ended September 30, 2016, was $906,000 compared to $938,000 in 2015, a decrease of 3.4%. Dougherty’s initial stores reported EBITDA of $434,000 for the third quarter ended September 30, 2016, compared to $521,000 in 2015, a decrease of 16.7%. For the nine months ended September 30, 2016, EBITDA for the initial stores was $1,545,000 compared to $1,493,000 in 2015, an increase of 3.5%. Third quarter revenue from acquisition stores increased $36,000 year over year at 20.7 percent margins. Revenue from acquisition stores for the nine months ended September 30, 2016 increased $3,603,000 at 21.4 percent margins. Acquisition store EBITDA for the third quarter of 2016 was $94,000 and $154,000 for the nine months ended September 30, 2016. The following chart summaries Dougherty’s Healthcare segment comparing the Company’s two initial pharmacies and the five pharmacies acquired since 2014, along with Dougherty’s corporate overhead. The Company’s Other division includes corporate overhead expenses and dividend income from its remaining real estate investments. This division reported negative EBITDA of ($118,000) for the third quarter of 2016 compared to ($138,000) in 2015 and negative EBITDA of ($403,000) for the nine months ended September 30, 2016 compared to ($474,000) in 2015. Mark Heil, President and CFO, added, “We are actively working to counter the headwinds from lower reimbursement rates and are focused on enhancing our performance for the fourth quarter and beyond. Our strategic internal directives include negotiating better rates from our vendors and pharmaceutical distributors, reducing costs to improve SG&A, and enhancing performance from our pharmacy locations. We expect these initiatives to lead to improved results going forward.” Jim Leslie, Chairman of Ascendant, commented, “As we focus on improving our operational and financial results, the board has taken an important step to continue building additional value and trust with our shareholders. On November 9, the board of directors of Ascendant approved a 1 percent stock dividend for our shareholders. The stock dividend will be payable on December 12, 2016, to holders of record as of December 5, 2016. This represents the third consecutive annual stock dividend paid to shareholders of Ascendant. “As stated in previous quarters, our long-term focus continues to be on growing our healthcare business through the opportunistic acquisition of well-run community pharmacies. Consequently, we expect to resume our acquisition of additional well-run independent pharmacies in 2017. We remain committed to growing our pharmacy business and producing solid shareholder returns over time.” EBITDA is calculated as net income (loss) before deducting interest, taxes, depreciation and amortization. Although EBITDA is not a measure of actual cash flow because it does not consider changes in assets and liabilities that may impact cash balances, the Company’s management reviews these non-GAAP financial measures internally to evaluate the Company’s performance and manage the operations. Additionally, the Company believes it is a useful metric to evaluate operating performance and has therefore included such measures in the reporting of operating results. Ascendant Solutions, Inc. is a value-oriented investment firm focused on successfully acquiring, managing and growing community-based pharmacies in the Southwest Region. Ascendant currently has approximately $43 million in net operating loss carryforwards which can be used to shelter future income, thus enhancing free cash flow or debt service capabilities. Interested investors can access financials and stock trading information for Ascendant at OTCMarkets.com or at www.ascendantsolutions.com. This press release contains forward-looking statements within the meaning of the Securities Act of 1933, the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's current expectations, projections, estimates and assumptions. These forward-looking statements may be identified by words such as "expects," "believes," "anticipates" and similar expressions. Forward-looking statements involve risks and uncertainties that may cause future results to differ materially from those suggested by the forward-looking statements. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect any future events or circumstances.